Real-world experience in UK centres
NEWCASTLE:
A retrospective review recorded between 8–16 weeks (N=100)4
MANCHESTER (SALFORD):
A retrospective review at 3 and 6 months (N=164)2
LONDON SPECIALIST ECZEMA CLINIC:
A prospective 52-week observational study (N=100)3
LONDON ROYAL FREE HOSPITAL:
Outcomes measured at 4, 12, 24, and 52 weeks (N=65)6
SOUTHAMPTON
Outcomes measured at 1 and 4 months (N=29)5
Find out more about real-world experience in UK centres
DUPIXENT has an extensive Phase 3 clinical trial programme with improvements in lesion extent and severity, itch and quality-of-life1
Reimbursement
Learn about the reimbursement of DUPIXENT in England, Wales and Scotland.
Find out more
- DUPIXENT Summary of Product Characteristics. September 2021.
- Kreeshan FC, et al. Dermatol Ther (Heidelb). 2021;11(1):149–160.
- Sears AV, et al. Br J Dermatol. 2021;184(4):755–757.
- Bajwa D, et al. Real-world response to dupilumab in patients with atopic dermatitis: a retrospective review of 100 patients. Poster P81. Presented at the 101st British Association of Dermatologists Annual meeting, Virtual, July 6–8 2021.
- O’Driscoll D, et al. Dupilumab, an incoming treatment for adolescents with atopic dermatitis: experience from a tertiary eczema. Abstract PA01. Presented at the 99th British Association of Dermatologists Annual meeting, Liverpool, July 2–4 2019.
- Gardette E, et al. Real-world experience of dupilumab for the treatment of severe recalcitrant atopic dermatitis in a tertiary centre. Abstract O06. Presented at the 99th British Association of Dermatologists Annual meeting, Liverpool, July 2–4 2019.
AD, atopic dermatitis; UK, United Kingdom.
References
MAT-IE-2101031(v4.0) | Date of preparation: February 2022
